Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain

NeuroReport

Volumn 11, Issue 3, 2000, Pages 551-555

  Nakahara, Tatsuo ^a   Kuroki, Toshihide ^b   Hashimoto, Kijiro ^c   Hondo, Hisao ^a   Tsutsumi, Tetsuyuki ^c   Motomura, Keisuke ^c   Ueki, Hiroshi ^c   Hirano, Makoto ^c   Uchimura, Hideyuki ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Hizen National Hospital   (Japan)

Author keywords

Arc; Clozapine; Nucleus accumbens; Olanzapine; Phencyclidine; Posterior cingulate cortex; Prefrontal cortex; Risperidone; Striatum

Indexed keywords

HALOPERIDOL; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN ARC; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CINGULATE GYRUS; CONTROLLED STUDY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033999801     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200002280-00025     Document Type: Article

References (25)

1. Kane J, Honigfeld G, Singer J and Meltzer HY. Arch Gen Psychiatry 45, 789-796 (1988).
2. Jentsch JD and Roth RH. Neuropsychopharmacology 20, 201-225 (1999).
3. Maurel-Remy S, Bervoets K and Millan MJ. Eur J Pharmacol 280, R1-R11 (1995).
4. Tsutsumi T, Hirano M, Matsumoto T et al. Clin Neuropharmacology 18, 64-71 (1995).
5. Bakshi VP, Swerdlow NR and Geyer MA. J Pharmacol Exp Ther 271, 787-794 (1994).
6. Swerdlow NR, Bakshi VP and Geyer MA. J Pharmacol Exp Ther 279, 1290-1299 (1996).
7. Lyford GL, Yamagata K, Kaufmann WE et al. Neuron 14, 433-445 (1995).
8. Link W, Konietzko U, Kauselmann G et al. Proc Nat Acad Sci USA 92, 5734-5738 (1995).
9. Kodama M, Akiyama K, Ujike H et al. Brain Res 796, 273-283 (1998).
10. Steward O, Wallace CS, Lyford G L and Worley P F. Neuron 21, 741-751 (1998).
11. Fosnaugh JS, Bhat RV, Yamagata K et al. J Neurochem 64, 2377-2380 (1995).
12. Berke JD, Paletzki RF, Aronson GJ et al. J Neurosci 18, 5301-5310 (1998).
13. Nakahara T, Kuroki T, Hondo H et al., Mol Brain Res 73, 193-197 (1999).
14. Nakaaahara T, Hirano M, Matsumoto T et al. Neurochem Res 15, 609-611 (1990).
15. Nakahara T, Nakamura K, Tsutsumi T et al. Mol Brain Res 61, 238-242 (1998).
16. Hondo H, Yonezawa Y, Nakahara T et al. Brain Res 633, 337-342 (1994).
17. Umino A, Takahashi K and Nishikawa T. Br J Pharmacol 124, 377-385 (1998).
18. Kuroki T, Meltzer HY and Ichikawa J. J Pharmacol Exp Ther 288, 774-781 (1999).
19. Nabeshima T, Ishikawa K, Yamaguchi K et al. Biochem Pharmacol 37, 3277-3283 (1988).
20. Schotte A, Janssen PFM, Gommeren W et al. Psychopharmacology 124, 57-73 (1996).
21. Stockmeier CA, DiCarlo JJ, Zhang Y et al. J Pharmacol Exp Ther 266, 1374-1384 (1993).
22. Jakab RL and Goldman-Rakic PS. Proc Natl Acad Sci USA 95, 735-740 (1998).
23. Bymaster FP, Calligaro DO, Falcone JF et al. Neuropsychopharmacology 14, 87-96 (1996).
24. Sharp FR, Butman M, Wang S et al. J Neurosci Res 33, 605-616 (1992).
25. Olney JW, Labruyere J, Wang G et al. Science 254, 1515-1518 (1991).